Fate Therapeutics (FATE) Total Non-Current Liabilities (2012 - 2026)

Fate Therapeutics has reported Total Non-Current Liabilities for 15 years, with the latest figure at $103.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 6.29% year-over-year to $103.1 million; the trailing twelve-month figure through Mar 2026 stood at $103.1 million (down 6.29% YoY), and the FY2025 full-year result was $109.6 million, down 9.72% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $103.1 million, down from $109.6 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $230.5 million in Q3 2022, with the low at $103.0 million in Q3 2025.
• Historically, Total Non-Current Liabilities has averaged $148.4 million across 5 years, with a median of $137.8 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities decreased 0.31% — and 2023, when it plunged 39.14%.
• Fate Therapeutics' Total Non-Current Liabilities stood at $217.8 million in 2022, then tumbled by 36.72% to $137.8 million in 2023, then fell by 11.87% to $121.4 million in 2024, then declined by 9.72% to $109.6 million in 2025, then decreased by 5.97% to $103.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $103.1 million (Q1 2026), $109.6 million (Q4 2025), and $103.0 million (Q3 2025), per Business Quant data.